LIVIVO - Search results -

Search results

Result 1 - 10 of total 21

Search options

Article ; Online: Is subcutaneous insulin administration adequate for the management of hyperglycemic crisis in COVID-19?

Permana, Hikmat / Soetedjo, Nanny Natalia M

2020 Volume 14, Issue 5, Page(s) 947–948

Abstract: There is a desperate need to explore different insulin administration strategies, particularly in coronavirus disease 2019 (COVID-19) patients with hyperglycemic crisis. Noteworthily, diabetes mellitus (DM) and poorly controlled blood glucose increase ... ...

Abstract	There is a desperate need to explore different insulin administration strategies, particularly in coronavirus disease 2019 (COVID-19) patients with hyperglycemic crisis. Noteworthily, diabetes mellitus (DM) and poorly controlled blood glucose increase the risk of mortality and severity of COVID-19. Intravenous (IV) insulin administration with hourly monitoring of blood glucose is the ideal approach in managing patients with hyperglycemic crisis, but it is not judicious to be applied in developing countries where shortage of personal protective equipment (PPE) is a major issue. Furthermore, increasing the probability of "already greater risks" for doctors or other healthcare workers contracting COVID-19 seems inappropriate. Thus, an alternative administration strategy and more moderate glucose monitoring to reduce the contact exposure of healthcare workers with COVID-19 patients, by ensuring appropriate blood glucose levels, needs to be performed in this critical pandemic era. Subcutaneous (SC) rapid-acting insulin analog administration could presumably be a solution to this contentious issue.
MeSH term(s)	Betacoronavirus/isolation & purification ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/epidemiology ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Disease Management ; Humans ; Hyperglycemia/drug therapy ; Hyperglycemia/epidemiology ; Hyperglycemia/virology ; Hypoglycemic Agents/administration & dosage ; Injections, Subcutaneous ; Insulin/administration & dosage ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; SARS-CoV-2
Chemical Substances	Hypoglycemic Agents ; Insulin
Keywords	covid19
Language	English
Publishing date	2020-06-18
Publishing country	Netherlands
Document type	Letter
ZDB-ID	2273766-2
ISSN	1878-0334 ; 1871-4021
ISSN (online)	1878-0334
ISSN	1871-4021
DOI	10.1016/j.dsx.2020.06.032
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Antibody response following SARS-CoV-2 vaccination among patients with type 2 diabetes mellitus: A systematic review.

Soetedjo, Nanny Natalia M / Iryaningrum, Maria Riastuti / Lawrensia, Sherly / Permana, Hikmat

Diabetes & metabolic syndrome

2022 Volume 16, Issue 2, Page(s) 102406

Abstract: Background and aim: DM patients' antibody response after the COVID-19 vaccine is still unknown amid the COVID-19 vaccination rollout. This study aimed to explore the SARS-CoV-2 antibody response or seropositivity among DM patients following the COVID-19 ...

Abstract	Background and aim: DM patients' antibody response after the COVID-19 vaccine is still unknown amid the COVID-19 vaccination rollout. This study aimed to explore the SARS-CoV-2 antibody response or seropositivity among DM patients following the COVID-19 vaccine administration. Methods: We performed a systematic review of the literature consisting of observational or cross-sectional studies, which reported the antibody serology or seropositivity among DM patients by following the PRISMA 2020 guidelines. Results: Eight studies with a total of 64468 patients were identified, and 5156 (7.9%) of them had diabetes. Most studies showed that antibody response and seropositivity in DM patients were lower than healthy population after one until four weeks following full COVID-19 vaccination dose. Conclusion: The antibody response and seropositivity after the COVID-19 vaccine in DM patients were lower than in healthy subjects. Therefore, DM patients are expected to receive vaccines according to the dose and schedule appropriately and might be prioritized to receive vaccine boosters.
MeSH term(s)	Antibodies, Viral/blood ; Antibody Formation/immunology ; BNT162 Vaccine/immunology ; COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19 Vaccines/immunology ; Diabetes Mellitus, Type 2/epidemiology ; Diabetes Mellitus, Type 2/immunology ; SARS-CoV-2/immunology ; Vaccination
Chemical Substances	Antibodies, Viral ; COVID-19 Vaccines ; BNT162 Vaccine (N38TVC63NU)
Language	English
Publishing date	2022-01-21
Publishing country	Netherlands
Document type	Journal Article ; Systematic Review
ZDB-ID	2273766-2
ISSN	1878-0334 ; 1871-4021
ISSN (online)	1878-0334
ISSN	1871-4021
DOI	10.1016/j.dsx.2022.102406
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Is subcutaneous insulin administration adequate for the management of hyperglycemic crisis in COVID-19?

Permana, Hikmat / Soetedjo, Nanny Natalia M.

Diabetes & Metabolic Syndrome: Clinical Research & Reviews

2020 Volume 14, Issue 5, Page(s) 947–948

Keywords	Internal Medicine ; Endocrinology, Diabetes and Metabolism ; General Medicine ; covid19
Language	English
Publisher	Elsevier BV
Publishing country	us
Document type	Article ; Online
ZDB-ID	2273766-2
ISSN	1878-0334 ; 1871-4021
ISSN (online)	1878-0334
ISSN	1871-4021
DOI	10.1016/j.dsx.2020.06.032
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Diabetes and Mortality among Patients with Chronic Kidney Disease and COVID-19: A Systematic Review, Meta-analysis, and Meta-regression.

Iryaningrum, Maria R / Supriyadi, Rudi / Lawrensia, Sherly / Henrina, Joshua / Soetedjo, Nanny Natalia M

Indian journal of nephrology

2022 Volume 32, Issue 4, Page(s) 327–333

Abstract: Introduction: Patients with kidney disease and COVID-19, whether on hemodialysis (HD) or not, have a higher risk of contracting COVID-19 accompanied by a higher mortality rate due to suppressed immune functions. Diabetes, one of the ubiquitous etiology ... ...

Abstract	Introduction: Patients with kidney disease and COVID-19, whether on hemodialysis (HD) or not, have a higher risk of contracting COVID-19 accompanied by a higher mortality rate due to suppressed immune functions. Diabetes, one of the ubiquitous etiology of kidney disease, is also associated with a composite of poor outcomes. Methods: Meta-analysis and meta-regression of 13 articles on COVID-19 patients with chronic kidney disease, with information on diabetes and mortality were performed using Review Manager 5.4 and OpenMetaAnalyst. Results: The meta-analysis of a pooled subject of 18,822 patients showed that the presence of diabetes in CKD patients with COVID-19 was associated with an increased risk of mortality (RR 1.41 (1.15, 1.72); Conclusions: Diabetes was associated with higher mortality risk among CKD patients, primarily those who did not need RRT.
Language	English
Publishing date	2022-05-20
Publishing country	India
Document type	Journal Article
ZDB-ID	2134388-3
ISSN	1998-3662 ; 0971-4065
ISSN (online)	1998-3662
ISSN	0971-4065
DOI	10.4103/ijn.ijn_293_21
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article: Is subcutaneous insulin administration adequate for the management of hyperglycemic crisis in COVID-19?

Permana, Hikmat / Soetedjo, Nanny Natalia M

Diabetes Metab Syndr

Abstract	There is a desperate need to explore different insulin administration strategies, particularly in coronavirus disease 2019 (COVID-19) patients with hyperglycemic crisis. Noteworthily, diabetes mellitus (DM) and poorly controlled blood glucose increase the risk of mortality and severity of COVID-19. Intravenous (IV) insulin administration with hourly monitoring of blood glucose is the ideal approach in managing patients with hyperglycemic crisis, but it is not judicious to be applied in developing countries where shortage of personal protective equipment (PPE) is a major issue. Furthermore, increasing the probability of "already greater risks" for doctors or other healthcare workers contracting COVID-19 seems inappropriate. Thus, an alternative administration strategy and more moderate glucose monitoring to reduce the contact exposure of healthcare workers with COVID-19 patients, by ensuring appropriate blood glucose levels, needs to be performed in this critical pandemic era. Subcutaneous (SC) rapid-acting insulin analog administration could presumably be a solution to this contentious issue.
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #603775
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.

Permana, Hikmat / Soetedjo, Nanny Natalia Mulyani / Yanto, Theo Audi / Tendean, Marshell / Hariyanto, Timotius Ivan / Suastika, Ketut

Expert review of endocrinology & metabolism

2024 Volume 19, Issue 1, Page(s) 89–98

Abstract: Background: A new medication for type 2 diabetes mellitus (T2DM) called imeglimin can target all three organs involved in the pathogenesis of DM, namely the liver, skeletal muscles, and pancreas. This research seeks to examine the most efficacious and ... ...

Abstract	Background: A new medication for type 2 diabetes mellitus (T2DM) called imeglimin can target all three organs involved in the pathogenesis of DM, namely the liver, skeletal muscles, and pancreas. This research seeks to examine the most efficacious and safe dose of imeglimin for the management of T2DM. Research design and methods: Using particular keywords, we searched the CENTRAL, Medline, Scopus, and ClinicalTrials.gov databases for pertinent literature. The results of continuous variables were pooled into the mean difference (MD) and dichotomous variables into odds ratio (OR) along with their 95% confidence intervals (95% CI) using fixed-effect models. Results: Our pooled analysis revealed that imeglimin 1000 mg twice daily [MD -0.90% Conclusions: Our study suggests that imeglimin 1000 mg twice daily may offer the most optimum therapeutic effects for glycemic control without compromising its safety profiles.
MeSH term(s)	Humans ; Diabetes Mellitus, Type 2/drug therapy ; Hypoglycemic Agents/therapeutic use ; Randomized Controlled Trials as Topic ; Triazines/therapeutic use
Chemical Substances	Hypoglycemic Agents ; imeglimin (UU226QGU97) ; Triazines
Language	English
Publishing date	2024-01-01
Publishing country	England
Document type	Systematic Review ; Meta-Analysis ; Journal Article ; Review
ISSN	1744-8417
ISSN (online)	1744-8417
DOI	10.1080/17446651.2023.2290488
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Anti-SARS-CoV-2 Antibody Level Is Associated with a History of COVID-19 Infection and mRNA Vaccination in Patients with Diabetes.

Hataul, Is Asma'ul Haq / Soetedjo, Nanny Natalia M / Debora, Josephine / Tiara, Marita Restie / Djauhari, Hofiya / Susandi, Evan / Alisjahbana, Bachti / Wisaksana, Rudi / Permana, Hikmat

Vaccines

2023 Volume 11, Issue 9

Abstract: Type 2 diabetes mellitus (T2DM) is associated with higher severity and mortality in SARS-CoV-2 infections. Vaccination has been encouraged to boost immunity and prevent these unfortunate outcomes. Few studies have evaluated antibody levels after COVID-19 ...

Abstract	Type 2 diabetes mellitus (T2DM) is associated with higher severity and mortality in SARS-CoV-2 infections. Vaccination has been encouraged to boost immunity and prevent these unfortunate outcomes. Few studies have evaluated antibody levels after COVID-19 vaccination in patients with T2DM. Therefore, we examined the vaccination status and anti-SARS-CoV-2 antibody levels to identify the factors that affect the antibody levels in patients with T2DM. This cross-sectional study was conducted at the Dr. Hasan Sadikin Hospital and Bandung Kiwari Hospital, Bandung, West Java, Indonesia, between October and November 2022. Adult participants with and without T2DM were tested for SARS-CoV-2 antibodies using a point-of-care quantitative immunochromatographic assay. We enrolled 289 participants: 201 participants with T2DM and 88 participants without T2DM. The T2DM participants had a lower vaccination rate compared with the non-T2DM participants. However, no significant differences in antibody levels were observed between the two groups. Higher antibody levels among the T2DM participants were associated with mRNA vaccination and a history of COVID-19 illness. The lower antibody response observed among the T2DM participants with chronic obstructive pulmonary disease suggests that such patients may need antibody level measurement and an additional booster vaccine.
Language	English
Publishing date	2023-08-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2703319-3
ISSN	2076-393X
ISSN	2076-393X
DOI	10.3390/vaccines11091424
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Anti-SARS-CoV-2 Antibody Level Is Associated with a History of COVID-19 Infection and mRNA Vaccination in Patients with Diabetes

Is Asma’ul Haq Hataul / Nanny Natalia M. Soetedjo / Josephine Debora / Marita Restie Tiara / Hofiya Djauhari / Evan Susandi / Bachti Alisjahbana / Rudi Wisaksana / Hikmat Permana

Vaccines, Vol 11, Iss 1424, p

2023 Volume 1424

Abstract	Type 2 diabetes mellitus (T2DM) is associated with higher severity and mortality in SARS-CoV-2 infections. Vaccination has been encouraged to boost immunity and prevent these unfortunate outcomes. Few studies have evaluated antibody levels after COVID-19 vaccination in patients with T2DM. Therefore, we examined the vaccination status and anti-SARS-CoV-2 antibody levels to identify the factors that affect the antibody levels in patients with T2DM. This cross-sectional study was conducted at the Dr. Hasan Sadikin Hospital and Bandung Kiwari Hospital, Bandung, West Java, Indonesia, between October and November 2022. Adult participants with and without T2DM were tested for SARS-CoV-2 antibodies using a point-of-care quantitative immunochromatographic assay. We enrolled 289 participants: 201 participants with T2DM and 88 participants without T2DM. The T2DM participants had a lower vaccination rate compared with the non-T2DM participants. However, no significant differences in antibody levels were observed between the two groups. Higher antibody levels among the T2DM participants were associated with mRNA vaccination and a history of COVID-19 illness. The lower antibody response observed among the T2DM participants with chronic obstructive pulmonary disease suggests that such patients may need antibody level measurement and an additional booster vaccine.
Keywords	COVID-19 ; diabetes ; humoral immunity ; vaccines ; antibody ; Medicine ; R
Subject code	150
Language	English
Publishing date	2023-08-01T00:00:00Z
Publisher	MDPI AG
Document type	Article ; Online
Database	BASE - Bielefeld Academic Search Engine (life sciences selection)

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.

Permana, Hikmat / Huang, Ian / Purwiga, Aga / Kusumawardhani, Nuraini Yasmin / Sihite, Teddy Arnold / Martanto, Erwan / Wisaksana, Rudi / Soetedjo, Nanny Natalia M

Pharmacological reports : PR

2021 Volume 73, Issue 3, Page(s) 769–780

Abstract: Background and aims: The idea of treating COVID-19 with statins is biologically plausible, although it is still controversial. The systematic review and meta-analysis aimed to address the association between the use of statins and risk of mortality in ... ...

Abstract	Background and aims: The idea of treating COVID-19 with statins is biologically plausible, although it is still controversial. The systematic review and meta-analysis aimed to address the association between the use of statins and risk of mortality in patients with COVID-19. Methods: Several electronic databases, including PubMed, SCOPUS, EuropePMC, and the Cochrane Central Register of Controlled Trials, with relevant keywords up to 11 November 2020, were used to perform a systematic literature search. This study included research papers containing samples of adult COVID-19 patients who had data on statin use and recorded mortality as their outcome of interest. Risk estimates of mortality in statin users versus non-statin users were pooled across studies using inverse-variance weighted DerSimonian-Laird random-effect models. Results: Thirteen studies with a total of 52,122 patients were included in the final qualitative and quantitative analysis. Eight studies reported in-hospital use of statins; meanwhile, the remaining studies reported pre-admission use of statins. In-hospital use of statin was associated with a reduced risk of mortality (RR 0.54, 95% CI 0.50-0.58, p < 0.00001; I Conclusion: This meta-analysis showed that in-hospital use of statins was associated with a reduced risk of mortality in patients with COVID-19.
MeSH term(s)	COVID-19/drug therapy ; COVID-19/mortality ; COVID-19/virology ; Evaluation Studies as Topic ; Hospitals ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Risk ; SARS-CoV-2/pathogenicity
Chemical Substances	Hydroxymethylglutaryl-CoA Reductase Inhibitors
Language	English
Publishing date	2021-02-20
Publishing country	Switzerland
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2186248-5
ISSN	1734-1140
ISSN	1734-1140
DOI	10.1007/s43440-021-00233-3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 861: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The Association Between Chronic Kidney Disease and New Onset Renal Replacement Therapy on the Outcome of COVID-19 Patients: A Meta-analysis.

Pranata, Raymond / Supriyadi, Rudi / Huang, Ian / Permana, Hikmat / Lim, Michael Anthonius / Yonas, Emir / Soetedjo, Nanny Natalia M / Lukito, Antonia Anna

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

2020 Volume 14, Page(s) 1179548420959165

Abstract: Objective: The aim of the study was to evaluate the association between chronic kidney disease (CKD) and new onset renal replacement therapy (RRT) with the outcome of Coronavirus Disease 2019 (COVID-19) in patients.: Methodology: A systematic ... ...

Abstract	Objective: The aim of the study was to evaluate the association between chronic kidney disease (CKD) and new onset renal replacement therapy (RRT) with the outcome of Coronavirus Disease 2019 (COVID-19) in patients. Methodology: A systematic literature search from several databases was performed on studies that assessed CKD, use of RRT, and the outcome of COVID-19. The composite of poor outcome consisted of mortality, severe COVID-19, acute respiratory distress syndrome (ARDS), need for intensive care, and use of mechanical ventilator. Results: Nineteen studies with a total of 7216 patients were included. CKD was associated with increased composite poor outcome (RR 2.63 [1.33, 5.17], Conclusion: CKD and new-onset RRT were associated with poor outcome in patients with COVID-19.
Keywords	covid19
Language	English
Publishing date	2020-09-17
Publishing country	United States
Document type	Journal Article
ZDB-ID	2583465-4
ISSN	1179-5484
ISSN	1179-5484
DOI	10.1177/1179548420959165
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito